secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2025-10-21T23:59:59+00:00
Accession:  0001615219-25-000148
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Salarius grants $225K transaction bonus to Acting CEO Rosenblum tied to Decoy merger
--------------------------------------------------------------------------------

- Board approved $225,000 cash bonus for Acting CEO/CFO Mark J. Rosenblum.
- Bonus payable upon closing of the previously announced merger with Decoy Therapeutics.
- Payment subject to Rosenblum's continued employment through the closing date.
- Rosenblum holds dual roles as Acting CEO and Executive VP/CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000148/0001615219-25-000148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000148/flks-20251021.htm
  HTML page:      https://secwatch.observer/filing/0001615219-25-000148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer